MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$1,494,718
Unit: Dollar
Positive Cash Flow Breakdown
Accounts payable
Unrealized loss on digital asset...
Net proceeds from issuance of co...
Others
Negative Cash Flow Breakdown
Accrued expenses
Prepaid expenses and other
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-3,265,494
-3,377,179
-3,358,938
-3,436,573
Depreciation
301
301
301
301
Non-cash lease expense for right-of-use assets
-
-
0
24,318
Unrealized loss on digital assets
768,348
59,824
-
-
Unrealized gain on digital assets at fair value
-
-
295,180
-
Realized loss on sale of digital assets
159,005
-
-
-
Stock-based compensation
92,105
95,963
123,541
303,047
Prepaid expenses and other
156,960
113,444
-144,423
55,606
Operating lease liability
-
-
0
-21,832
Accounts payable
819,068
-216,426
329,624
-58,582
Accrued expenses
-412,258
-39,734
155,651
-239,437
Net cash used in operating activities
-1,995,885
-3,590,695
-2,900,578
-3,484,364
Purchase of digital assets
0
500,000
850,000
-
Cash received from sale of digital assets
186,000
-
-
-
Net cash used in investing activities
186,000
-500,000
-850,000
-
Net proceeds from the sale of stock and exercise of warrants
-
-
-
2,859,916
Net proceeds from issuance of common stock
315,167
245,103
16,597,831
-
Shares withheld to pay taxes on stock-based compensation
0
320
0
0
Payment of finance lease obligation
-
-
0
3,752
Net cash provided by financing activities
315,167
244,783
2,979,113
2,856,164
Net (decrease) increase in cash and cash equivalents
-1,494,718
-3,845,912
-771,465
-628,200
Cash and cash equivalents - beginning of period
1,691,043
5,536,955
6,308,420
1,191,325
Cash and cash equivalents - end of period
196,325
1,691,043
5,536,955
6,308,420
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net proceeds from
issuance of common stock
$315,167
Cash received from
sale of digital...
$186,000
Net cash provided by
financing activities
$315,167
(-97.07%↓ Y/Y)
Net cash used in
investing activities
$186,000
Net (decrease)
increase in cash and cash...
-$1,494,718
(-126.02%↓ Y/Y)
Canceled cashflow
$501,167
Accounts payable
$819,068
(961.03%↑ Y/Y)
Unrealized loss on digital
assets
$768,348
Realized loss on sale of
digital assets
$159,005
Stock-based compensation
$92,105
(-78.63%↓ Y/Y)
Depreciation
$301
(-50.00%↓ Y/Y)
Net cash used in
operating activities
-$1,995,885
(60.08%↑ Y/Y)
Canceled cashflow
$1,838,827
Net loss
-$3,265,494
(51.75%↑ Y/Y)
Accrued expenses
-$412,258
(-160.23%↓ Y/Y)
Prepaid expenses and
other
$156,960
(121.04%↑ Y/Y)
Buy us a coffee
Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA)